Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 5/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20878395 | 1.00 | FDPS (0.33) | FDPSLMNAOPRM1OPRD1OPRK1 | |
| SCHEMBL20094575 | 1.00 | FDPS (0.33) | FDPSLMNAOPRM1OPRD1OPRK1 | |
| SCHEMBL24599674 | 0.86 | FDPS (0.41) | FDPSLMNAOPRM1DNM1 | |
| SCHEMBL23969864 | 0.86 | FDPS (0.41) | FDPSLMNAOPRM1DNM1 | |
| SCHEMBL14238528 | 0.86 | FDPS (0.41) | FDPSLMNAOPRM1DNM1 | |
| SCHEMBL6685587 | 0.86 | FDPS (0.41) | FDPSLMNAOPRM1DNM1 | |
| SCHEMBL19288679 | 0.84 | HRH3 (0.33) | — | |
| SCHEMBL20094671 | 0.80 | CA2 (0.37) | FDPSCA2 | |
| SCHEMBL24040161 | 0.79 | OPRM1 (0.38) | FDPSLMNAOPRM1DNM1 | |
| SCHEMBL21498956 | 0.79 | MC4R (0.41) | FDPSLMNAOPRM1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111939-A1 | 7-(MORPHOLIN-4-YL)PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES WHICH ARE USEFUL FOR THE TREATMENT OF IMMUNE OR INFALMMATORY DISEASES OR CANCER | CELON PHARMA S.A. (PL) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111939-A1 | 7-(MORPHOLIN-4-YL)PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES WHICH ARE USEFUL FOR THE TREATMENT OF IMMUNE OR INFALMMATORY DISEASES OR CANCER | AFF2, INF2, AFF1 | FDPS 27/4885LMNA 3993/4885OPRM1 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.